Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase III multicenter randomized trial evaluating Fuzuloparib in combination with Abiraterone acetate and prednisone versus placebo with Abiraterone acetate and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Fuzuloparib
• PREDNISONE (Prednisone)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING